List of Tables
Table 1. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Competitive Situation by Manufacturers in 2024
Table 4. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Antidiabetic Glucagon-like Peptide 1 Agonists, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Product Type & Application
Table 12. Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic Glucagon-like Peptide 1 Agonists as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2020-2025) & (K Units)
Table 18. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Region (2020-2025)
Table 19. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2026-2031) & (K Units)
Table 20. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Region (2026-2031)
Table 21. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Region (2020-2025)
Table 23. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Region (2026-2031)
Table 25. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) & (K Units)
Table 27. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2026-2031) & (K Units)
Table 28. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) & (K Units)
Table 32. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2026-2031) & (K Units)
Table 33. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Type (2020-2025)
Table 51. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Type (2026-2031)
Table 52. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type (2020-2025)
Table 53. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type (2026-2031)
Table 54. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Type (2020-2025)
Table 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Type (2026-2031)
Table 58. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Type (2020-2025)
Table 59. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Type (2026-2031)
Table 60. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Application (2020-2025)
Table 61. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Application (2026-2031)
Table 62. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Application (2020-2025)
Table 63. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Application (2026-2031)
Table 64. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Application (2020-2025)
Table 67. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Application (2026-2031)
Table 68. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Application (2020-2025)
Table 69. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Application (2026-2031)
Table 70. Novo Nordisk Company Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. AstraZeneca Company Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Eli Lily Company Information
Table 81. Eli Lily Description and Business Overview
Table 82. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 84. Eli Lily Recent Developments/Updates
Table 85. GSK Company Information
Table 86. GSK Description and Business Overview
Table 87. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 89. GSK Recent Developments/Updates
Table 90. Sanofi Company Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Bristol-Myers Squibb Company Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Abbott Laboratories Company Information
Table 101. Abbott Laboratories Description and Business Overview
Table 102. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 104. Abbott Laboratories Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Antidiabetic Glucagon-like Peptide 1 Agonists Distributors List
Table 108. Antidiabetic Glucagon-like Peptide 1 Agonists Customers List
Table 109. Antidiabetic Glucagon-like Peptide 1 Agonists Market Trends
Table 110. Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
Table 111. Antidiabetic Glucagon-like Peptide 1 Agonists Market Challenges
Table 112. Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antidiabetic Glucagon-like Peptide 1 Agonists
Figure 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Type: 2024 & 2031
Figure 4. Exenatied Product Picture
Figure 5. Liraglutide Product Picture
Figure 6. Lixisenatide Product Picture
Figure 7. Albiglutide Product Picture
Figure 8. Dulaglutide Product Picture
Figure 9. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Application: 2024 & 2031
Figure 11. Hospital
Figure 12. Pharmacy
Figure 13. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size (2020-2031) & (US$ Million)
Figure 15. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (2020-2031) & (K Units)
Figure 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (US$/Unit) & (2020-2031)
Figure 17. Antidiabetic Glucagon-like Peptide 1 Agonists Report Years Considered
Figure 18. Antidiabetic Glucagon-like Peptide 1 Agonists Sales Share by Manufacturers in 2024
Figure 19. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Antidiabetic Glucagon-like Peptide 1 Agonists Players: Market Share by Revenue in Antidiabetic Glucagon-like Peptide 1 Agonists in 2024
Figure 21. Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2020-2031)
Figure 24. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2020-2031)
Figure 25. United States Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2020-2031)
Figure 28. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2020-2031)
Figure 29. Germany Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Region (2020-2031)
Figure 36. China Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Indonesia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Thailand Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Malaysia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2020-2031)
Figure 46. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Type (2020-2031)
Figure 56. Global Revenue Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Type (2020-2031)
Figure 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Application (2020-2031)
Figure 59. Global Revenue Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Application (2020-2031)
Figure 60. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Application (2020-2031)
Figure 61. Antidiabetic Glucagon-like Peptide 1 Agonists Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
